03/2022 : New publication (Jean-Baptiste DELHORME / Isabelle GROSS)

This translational study shows that the transcription factor CDX2, which plays an essential role in the identity of intestinal cells, decreases the sensitivity to chemotherapy of patients with colorectal cancer by promoting the expression of genes involved in the elimination of cytotoxic molecules. It therefore opens the way to the development of new, more effective therapeutic strategies.

CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer

Jean-Baptiste Delhorme, Emilie Bersuder, Chloé Terciolo, Ourania Vlami, Marie-Pierrette Chenard, Elisabeth Martin, Serge Rohr, Cécile Brigand, Isabelle Duluc, Jean-Noël Freund, Isabelle Gross

Biomedicine & PharmacotherapyVolume 147, March 2022, 112630.

doi: 10.1016/j.biopha.2022.112630